Artal Group S.A. Bei Gene, Ltd. Transaction History

Artal Group S.A.

  • $214 Million
  • Q3 2024

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$129.52 - $174.32 $13.1 Million - $17.7 Million
-101,413 Reduced 25.05%
303,369 $43.3 Million
Q1 2024

May 13, 2024
BUY
$141.8 - $181.47 $42,823 - $54,803
302 Added 0.07%
404,782 $63.3 Million
Q4 2023

Feb 09, 2024
BUY
$158.67 - $201.58 $86,633 - $110,062
546 Added 0.14%
404,480 $73 Million
Q3 2023

Nov 13, 2023
SELL
$179.87 - $225.13 $1.54 Million - $1.93 Million
-8,562 Reduced 2.08%
403,934 $72.7 Million
Q2 2023

Aug 11, 2023
SELL
$178.3 - $266.78 $15.8 Million - $23.7 Million
-88,839 Reduced 17.72%
412,496 $73.5 Million
Q1 2023

May 12, 2023
SELL
$215.53 - $274.5 $21.3 Million - $27.1 Million
-98,665 Reduced 16.44%
501,335 $108 Million
Q4 2022

Feb 13, 2023
SELL
$125.51 - $229.3 $6.28 Million - $11.5 Million
-50,000 Reduced 7.69%
600,000 $132 Million
Q2 2022

Aug 11, 2022
SELL
$121.11 - $216.05 $1.82 Million - $3.24 Million
-15,000 Reduced 2.26%
650,000 $105 Million
Q1 2022

May 12, 2022
SELL
$146.52 - $269.56 $1.47 Million - $2.7 Million
-10,000 Reduced 1.48%
665,000 $125 Million
Q4 2021

Feb 11, 2022
BUY
$248.56 - $389.34 $6.21 Million - $9.73 Million
25,000 Added 3.85%
675,000 $183 Million
Q3 2021

Nov 12, 2021
SELL
$249.6 - $403.14 $49.9 Million - $80.6 Million
-200,000 Reduced 23.53%
650,000 $236 Million
Q1 2021

May 14, 2021
SELL
$260.64 - $382.12 $39.1 Million - $57.3 Million
-150,000 Reduced 15.0%
850,000 $296 Million
Q4 2020

Feb 11, 2021
BUY
$221.31 - $316.61 $22.1 Million - $31.7 Million
100,000 Added 11.11%
1,000,000 $258 Million
Q3 2020

Nov 13, 2020
BUY
$189.18 - $286.44 $9.46 Million - $14.3 Million
50,000 Added 5.88%
900,000 $258 Million
Q2 2020

Aug 14, 2020
BUY
$123.9 - $195.41 $24.8 Million - $39.1 Million
200,000 Added 30.77%
850,000 $160 Million
Q1 2020

May 14, 2020
BUY
$121.84 - $173.19 $1.22 Million - $1.73 Million
10,000 Added 1.56%
650,000 $80 Million
Q4 2019

Feb 13, 2020
SELL
$115.78 - $208.34 $1.16 Million - $2.08 Million
-10,000 Reduced 1.54%
640,000 $106 Million
Q2 2019

Aug 09, 2019
BUY
$113.99 - $146.86 $5.7 Million - $7.34 Million
50,000 Added 8.33%
650,000 $80.6 Million
Q3 2018

Nov 09, 2018
SELL
$152.62 - $189.66 $11.4 Million - $14.2 Million
-75,000 Reduced 11.11%
600,000 $103 Million
Q2 2018

Aug 10, 2018
BUY
$152.5 - $216.77 $11.4 Million - $16.3 Million
75,000 Added 12.5%
675,000 $104 Million
Q1 2018

May 10, 2018
BUY
$97.41 - $177.22 $29.2 Million - $53.2 Million
300,000 Added 100.0%
600,000 $101 Million
Q4 2017

Feb 09, 2018
BUY
$79.6 - $114.73 $5.97 Million - $8.6 Million
75,000 Added 33.33%
300,000 $29.3 Million
Q3 2017

Nov 08, 2017
BUY
$66.19 - $103.46 $14.9 Million - $23.3 Million
225,000
225,000 $23.3 Million

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email